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“Biology gives you a brain. Life turns it into a mind.” 
-  Jeffrey Eugenides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
ABSTRACT 
 
The development of the central nervous system relies on neural stem cells. How these stem 
cells either maintain their identity as self-renewing progenitors or differentiate into cells of 
the neuronal or glial lineage are fundamental questions. The work presented in this thesis 
investigates how different SOX transcription factors orchestrate the mechanisms and gene 
expression programs that govern these processes.  
In paper I, we investigate how SOX2, SOX3 and SOX11 regulate specific gene sets in 
embryonic stem cells (ESCs), neural progenitor cells (NPCs) and neurons, respectively. We 
propose a model of sequentially acting SOX transcription factors that control neural 
lineage-specific gene expression by predisposing gene sets to become activated in NPCs 
and during neuronal differentiation.  
In paper II, we expand our sequential binding model to cells of the glial lineage. Binding 
studies in NPCs and glial precursor cells (GPCs) show that astrocyte and oligodendrocyte 
specific gene sets are extensively preselected prior to the onset of gliogenesis, through 
prebinding of SOX3 and SOX9. This prebinding serves to prevent premature activation of a 
subset of genes, but also promotes the formation of permissive chromatin, which facilitates 
their activation at a later stage during astrocytic and oligodendrocytic differentiation.  
In paper III, we use ChIP-seq and RNA-seq analysis to investigate the binding profile of 
SOX2 in neural stem cells of four different tissues from two germlayers. We demonstrate 
that although SOX2 binds few regions that are common, the majority of its target regions 
are cell type specific. The target sites are enriched for distinct binding motifs of putative co-
factors that are either commonly expressed or cell type specific. Furthermore, the bound 
regions function as cis-regulatory modules (CRMs) that instruct tissue specific gene 
expression.  
In paper IV, we examine the initial binding events of SOX2 and FOXG1 during early 
reprogramming. When misexpressed alone in mouse embryonic fibroblasts (MEFs), FOXG1 
preferably targets chromatin regions that were already open in native MEFs. In contrast, 
SOX2 can target regions that were previously closed and inaccessible, hence displaying 
pioneering activity. When co-expressed, both factors potentiate each other’s binding to 
neural genes, while the regions that are co-targeted by SOX2 and FOXG1 together 
correspond to genes that are mainly associated with proliferation.  
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1   INTRODUCTION 
 
“The chief function of the body is to carry the brain around.”  This statement by Thomas A. 
Edison illustrates the significance of our most complex organ. Together with the spinal cord 
it makes up the central nervous system (CNS), which is the central control module of our 
body and mind. It coordinates our entire activity, from physical functions like motion, 
reflexes and hormone secretion to the processing of sensation and emotions, like the 
creation of memories, thoughts and feelings. The building blocks of the CNS are billions of 
nerve and glial cells. The human brain alone consists of close to 100 billion neurons and 
1000 billion glial cells, which are mostly astrocytes and oligodendrocytes. These cells 
originate from a common ancestor, the neural stem cell. Neural stem cells are self-renewing 
cells, which means that they divide and give rise to daughter cells while maintaining their 
undifferentiated state. At the same time they are multipotent, which means they have the 
capacity to develop into different cell types of the neural lineage, such as neurons, 
astrocytes or oligodendrocytes. Neural stem cells are mainly found in the embryonic 
nervous tissue, but some persist also in the adult CNS, where they provide a life-long 
source of neurons and glia. 
The two characteristic properties of neural stem cells, infinite self-renewal capacity and 
lineage specific differentiation, are tightly controlled by a network of various transcription 
factors. SOX transcription factors are essential regulators of both features. The 
differentiation of neural stem cells into neurons and glial cells is a multi-step process that 
involves lineage specification, the downregulation of proliferation markers, cell cycle exit, 
migration and the upregulation of neuronal or glial markers while repressing genes of 
alternative lineages. The involvement and requirement of different SOX proteins in each of 
these steps underlines their status as key regulators of CNS development and maintenance. 
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2   THE SOX FAMILY 
 
The founding member of the SOX family was first identified in 1990 as the sex determining 
gene on the Y-chromosome, Sry (Gubbay et al. 1990, Sinclair et al. 1990). As Sry is crucial 
for the male sex determination, mutations in Sry gene are associated with sex reversal in 
mice and humans. Since then, 20 different Sox genes have been identified in mice and 
humans (Schepers et al. 2002), which have been shown to play key roles in a variety of 
developmental processes. They are expressed during all phases of embryonic development 
and are well-established regulators of cell fate decisions (Kamachi & Kondoh 2013). 
 
2.1   PROTEIN STRUCTURE 
All SOX members are characterized by a 79 amino acid motif that encodes a high-mobility-
group (HMG) box, which allows them to bind chromatin in a sequence specific manner and 
thereby to function as transcription factors. This DNA-binding domain is highly conserved 
between the different SOX proteins as all SOX members share more than 50% amino acid 
identity with the SRY HMG box (Schepers et al. 2002). The 20 different mammalian SOX 
proteins are divided into 8 groups A-H based on their homology (Bowles et al. 2000). 
Members of the same group share more than 80 % sequence identity within the HMG 
domain, whereas sequence conservation among SOX proteins from different groups is 
poor, particularly outside the HMG box. Quite often, members within a group have similar 
biochemical properties, expression patterns and overlapping functions, while SOX factors 
from different groups display distinct biological properties. But despite this apparent 
redundancy, individual members show a selective binding of target genes and exert 
distinct, cell type specific functions (Bergsland et al. 2011 (paper I), Hagey et al. 2018 (paper 
III)). 
 
2.2   DOMAINS OUTSIDE THE HMG BOX 
Apart from the HMG box, some SOX transcription factors carry other structural elements, 
such as activation/repression domains and dimerization domains (Table 1). Transactivation 
domains have been identified in SOXB1, SOXC, SOXE and SOXF proteins (Lefebvre et al. 
2007, Bowles et al. 2000). While SOXB1 and SOXC members have only one transactivation 
domain at the C-terminal end, SOXE and SOXF proteins have two, one at the C-terminal 
end and one in the central part. In contrast, a repressor domain can be found in SOXB2 
group transcription factors (Uchikawa et al. 1999, Sandberg et al. 2005). 
Members of the SOXD and SOXE group are the best studied examples of dimerization 
among SOX proteins. They dimerize via different mechanisms: SOXD proteins have coiled-
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coiled domain, which allows them to dimerize in a DNA-independent fashion (Lefebvre 
2010). SOXE proteins are monomers in solution, but they have the ability to dimerize in a 
DNA-dependent fashion by cooperatively binding to adjacent sites. The spacing between 
the sites is variable, but 3-6 bp are preferred (Peirano et al. 2000, Bridgewater et al. 2003). 
They form either homodimers or heterodimers with each other, but not with non-SOXE 
members. Dimerization is achieved via a unique dimerization domain that precedes the 
HMG box (Schlierf et al. 2002). 
Surprisingly, a study by Xia et al. (2015) in neutrophils revealed that the SOXB1 member 
SOX2 can also form homodimers. 
 
Table 1. Classification of the SOX family in mammals 
Group Members Regulatory domain Other domains 
SOXA SRY Activation  
SOXB1 SOX1, SOX2, SOX3 Activation  
SOXB2 SOX14, SOX21 Repression  
SOXC SOX4, SOX11, SOX12 Activation  
SOXD SOX5, SOX6, SOX13 ------------ Coiled-coiled 
SOXE SOX8, SOX9, SOX10 Activation Dimerization 
SOXF SOX7, SOX17, SOX18 Activation  
SOXG SOX15 ------------  
SOXH SOX30 ------------  
 
2.3   THE MOLECULAR BASIS FOR DNA RECOGNITION BY SOX FACTORS 
In contrast to most other transcription factors, SOX proteins bind to the minor groove of the 
DNA. The binding occurs via the two L-shaped arms of the HMG domain, thereby inducing 
a bend of the DNA of 60-70°. The minor groove is widened, while the major groove is 
compressed, which facilitates helical unwinding (Werner et al. 1995). By altering the 
conformation of the DNA, SOX factors increase its protein accessibility and plasticity; 
designating them as architectural modifiers of the 3D chromatin structure. Interestingly, the 
degree of DNA bending was reported to be critical for the transcriptional output. Mutation 
analysis of the SOX2-HMG domain or the Fgf4-enhancer, a classic SOX2 target sequence, 
demonstrated that alterations of the typical SOX-induced DNA bending angle can change 
the potency of transcriptional activity and even dictate whether SOX2 functions as a 
transcriptional activator or repressor (Scaffidi & Bianchi, 2001). However, analysis of DNA 
elements bound to SOX2, SOX4, SOX9, SOX17 and SOX18 reported highly similar 
bending angles of the different SOX factors (Klaus et al. 2016). Thus, the selective binding 
of the different SOX transcription factors cannot be explained by differential DNA bending 
activity. 
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All SOX factors bind to a common consensus motif C(A/T)TTG(A/T)(A/T) (Harley et al. 1994). 
This motif is so short and degenerate that it is found abundantly throughout the genome. 
Even though this motif is preferred by all 20 Sox proteins, variations in the heptameric 
consensus site and flanking regions and an overall substantial degeneracy are tolerated 
(Mertin et al. 1999, Badis et al. 2009). Since there are no apparent differences in the motifs 
recognized by different SOX factors that would allow us to distinguish or determine target 
gene selectivity of individual SOX members, other mechanisms must account for their 
context dependent function.  
Indeed, a transcription factor with a non-palindromic six-base-pair recognition sequence will 
select close to 1,5 million sites in a genome of 3x109 base pairs, sixty times larger than 
protein-coding genes, while a combination of two factors will select only 360 regulatory 
target sites out of the entire genome (Kondoh & Kamachi 2010). As recognition sequences 
of transcription factors are generally degenerated, the actual genomic sites selected by the 
combination of two factors may correspond to the number of genes that are regulated. 
Hence, the main contributing factor to the multitude of non-redundant and cell-type 
specific functions of Sox proteins is their dynamic association with different partner factors. 
The particular combinations and partner switches dictate genome engagement, gene 
expression programs and the developmental traits driven by SOX transcription factors (Hou 
et al. 2017). 
 
2.4   PARTNER FACTORS 
SOX proteins bind DNA with weak affinity and low specificity and the binding of a SOX 
protein alone does normally not lead to activation of gene transcription. The regulatory 
function that SOX factors exert on their target genes depends heavily on the available 
partner protein. Those partnerships are not fixed, but rather dynamic and change regularly 
depending on the cellular context and maturation state of the cell. SOX proteins can 
interact with a variety of different partner factors, such as lineage specific transcription 
factors, chromatin modifying enzymes and architectural factors (Kondoh & Kamachi 2010, 
Wegner 2010). In the following sections I will elaborate on a few selected interactions as 
exemplified by SOX2. 
 
2.4.1   SOX2 and POU factors 
The best characterized example of a SOX partnership is that of SOX2 and the POU factor 
OCT4 (Pou5f1). The functional interaction between these two factors was discovered in 
1995, when Yuan et al. demonstrated the requirement for this heterodimeric complex for 
the embryonic stem cell (ESC) specific activity of the Ffg4 enhancer. The studies 
demonstrated that SOX2 and OCT4 bind cooperatively to two adjacent cis-regulatory 
elements separated by a 3-base spacer and that the spacing of those sites is critical for 
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complex formation and transactivation of the Fgf4 enhancer (Ambrosetti et al. 1997). 
Interestingly, while OCT1 can also form a complex with SOX2 on this Fgf4 enhancer, it is 
completely inactive. On the other hand, the combination of SOX11 and the POU factor 
BRN2 can activate the Fgf4 enhancer (Kuhlbrodt et al. 1998). 
Since then, many cases for a functional SOX2/OCT4 partnership have been found, e.g. at 
regulatory regions of ESC markers like Utf1, Sox2, Nanog and Pou5f1, but in all these cases 
the SOX2 site and the OCT4 site lack the 3-base spacer in between them (Nishimoto et al. 
1999, Tomioka et al. 2002, Rodda et al. 2005, Chew et al. 2005). Those genes are part of 
the core ESC regulatory circuits; thus, making SOX2 and OCT4 cooperativity fundamental 
for a stable stem cell state. Their status as core stem cell factors is further emphasized by 
the discovery that SOX2 and OCT4 can induce pluripotency in somatic cells, either in 
combination with other transcription factors (Takahashi & Yamanaka 2006) or even alone 
(Huangfu et al. 2008).  
SOX-POU partnerships are not only essential for the induction and maintenance of stem 
cells, but are also involved in the progression of developmental processes and the 
transition from one cell state to another. For example, as pluripotent embryonic stem cells 
transition to multipotent neural progenitor cells, OCT4 expression is silenced and SOX2 
partnership switches from OCT4 to BRN2 (Pou3f2) (Lodato et al. 2013). This partner switch 
represents just a glimpse of a much more extensive event. The SOX2 interactome changes 
dramatically as ESCs differentiate. Of the >60 proteins that are associated with SOX2 in 
ESCs, only 18 of these interactions were present 24 h after the induction of differentiation 
(Mallanna et al. 2010). 
 
2.4.2   SOX2 and PAX6 
A cooperative binding of SOX2 and a partner factor has also been observed in lens cells of 
the chicken eye. Here, SOX2 binds together with PAX6 to an enhancer of the ∂-crystallin 
gene, which results in the activation of this specific gene (Kamachi et al. 1995). Both factors 
bind to a composite site that consists of a SOX and a PAX binding sequence. A prerequisite 
for the interaction and subsequent activation of the gene is the precise spacing between 
the two binding sites (Kamachi et al. 2001). Interestingly, the PAX binding motif is only little 
similar to the consensus binding sequence of PAX6 and is bound poorly by PAX6 alone. 
Even though PAX6 binds this degenerate motif with low affinity and only in cooperation 
with SOX2, the complex shows a strong transactivation potential, whereas the replacement 
of the deviant PAX6 site with the consensus binding site abolished the transactivation 
potential despite stronger binding of PAX6. Furthermore, while SOX2 alone was able to 
bind the isolated enhancer in vitro, in vivo SOX2 binding was only observed in conjunction 
with PAX6 (Kamachi et al. 2001).  
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These findings demonstrate that 1) strong binding does not equal strong cooperativity or 
high activation potential and 2) the chromatin environment plays an important role in the 
engagement of transcription factors with DNA. 
 
2.4.3   SOX and chromatin regulators 
Multiple studies have shown an association of SOX factors with chromatin modifying 
enzymes and architectural factors. In 2011, Engelen et al. performed a proteomic analysis 
for SOX2-interacting proteins in neural progenitor cells. Among the 50 factors that 
physically interacted with SOX2 were proteins of the chromatin modifying complexes 
SWI/SNF and SMRT, as well as CHD7, a chromatin remodeling ATPase. In a comprehensive 
study from 2017, Chronis et al. investigated the molecular mechanisms that underlie the 
OCT4, SOX2, KLF4 and c-MYC induced reprogramming of mouse embryonic fibroblasts 
(MEF). They showed that, while the four OSKM factors predominantly bind to active 
somatic enhancers in the early stages of reprogramming, they immediately initiate their 
inactivation by recruiting the co-repressor HDAC1, a histone deacetylase. Further evidence 
for a SOX-co-repressor partnership comes from the Wegner lab, that showed the 
recruitment of co-repressors HDAC1 and CTBP2 to regulatory regions by SOXD member 
SOX5 in melanocytes (Stolt et al. 2008). 
On the other hand, SOX proteins do not only associate with co-repressors, but also with 
members of co-activator complexes. In particular, SOX2 and SOX9 have been shown to 
recruit and physically interact with transcriptional co-activators/histone acetylases, for 
instance p300/CBP, TIP60 and EYA1 (Tsuda et al 2003, Chen at al. 2008, Chronis et al. 
2017, Hattori et al. 2008, Zou et al. 2008). 
In summary, SOX proteins alone are normally not sufficient to activate or repress gene 
expression. Their target gene selectivity and regulatory function rather depends on the 
combination with a specific partner factor. This molecular versatility is the basis to our 
understanding of how the same SOX factor can exert different functions and play different 
roles in different biological contexts. 
 
2.5   REGULATION OF SOX EXPRESSION AND ACTIVITY 
The activity of SOX proteins is regulated at multiple levels. The main determinant of their 
functional activity is their interaction with partner factors, as discussed above. Furthermore, 
SOX factors act in a dose-dependent fashion (Pevny & Nicolis 2010, Hagey & Muhr 2014, 
Whittington et al. 2015, Prévostel & Blache 2017), which means their protein levels must be 
tightly controlled. Both of these traits are regulated via post-translational modifications. 
These covalent modifications influence whether and how SOX factors homo- and 
heterodimerize, and affect DNA-binding activity, transactivation, protein stability and 
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intracellular localization (Hou et al. 2017, Kamachi & Kondoh 2013, Bernard & Harley 2010). 
Modifications include phosphorylation, acetylation, sumoylation, glycosylation and 
methylation (Jeong et al. 2010, Van Hoof et al. 2009, Baltus et al. 2009, Tsuruzoe et al. 
2006, Jang et al. 2012, Zhao et al. 2011).  
In addition, SOX activity is controlled at the transcriptional level. The expression of SOX 
factors is coordinated by both intrinsic and extrinsic signaling pathways. SOX2 expression, 
for instance, is stimulated by TGFB-signaling in ESCs and by EGF and SHH signaling, as 
well as PAX6, in NPCs (Chen et al. 2008, Mullen et al. 2011, Favaro et al. 2009, Lengler et 
al. 2005). In contrast, thyroid hormone signaling suppresses SOX2 expression as NPCs 
differentiate (Lopez-Juarez et al. 2012). Furthermore, SOX proteins are known to auto-
regulate themselves or other SOX proteins ((Inoue et al. 2007, Kuzmichev et al. 2012, 
Amador-Arjona et al. 2015). To maintain ESCs in an undifferentiated state, SOX2 is auto-
regulated in a positive feedback-loop by itself and in complex with other transcription 
factors, including OCT4, NANOG, SMAD1 and STAT3. (Uchikawa et al. 2003, Miyagi et al. 
2006, Catena et al. 2004, Tomioka et al. 2002, Boyer et al. 2005, Chen et al. 2008). 
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3   SOX IN EMBRYONIC CNS DEVELOPMENT  
 
3.1   SOX2 IN EMBRYONIC STEM CELLS 
The development of a mammalian embryo begins with a totipotent zygote that undergoes 
a series of rapid cell divisions. The resulting multicellular morula further develops into the 
blastocyst. The formation of the blastocyst is the first event of cells acquiring spatially 
derived identities as the cells segregate into the inner cell mass (ICM) and trophectoderm. 
While the trophectoderm will form placental and extraembryonic tissue, the inner cell mass 
contains founder cells that will give rise to the embryo. As these founder cells have the 
ability to self-renew and develop into all three germ layers, they are true pluripotent stem 
cells. However, their pluripotent potential is a transient state confined to the blastocyst 
stage; and as embryogenesis proceeds, those cells will become progressively fate 
restricted. Embryonic stem cells (ESC) in culture are derived from those ICM cells and share 
many characteristics with them. But, in contrast to their in vivo counterparts, they are able to 
self-renew and amplify themselves during extended culture without compromising their 
pluripotency (Zhang & Cui 2014). 
Pluripotent stem cells are regulated by a comprehensive network of transcription factors. 
For instance, zygotic deletion of SOX2 leads to a failure to form the pluripotent ICM (Avilion 
et al., 2003). SOX2 is not only required for the induction, but also the maintenance of 
pluripotent stem cells, as deletion from already established ESCs results in loss of 
pluripotency and their aberrant differentiation into trophectoderm-like cells (Masui et al. 
2007, Kopp et al. 2008). This phenotype can be rescued by the overexpression of OCT4. 
One elementary role for SOX2 could therefore be the maintenance of a sufficient OCT4 
expression. Surprisingly, overexpression of SOX2 (2-fold) has a similar effect as ablation and 
also causes ESCs to differentiate. Consequently, SOX2 levels need to be tightly controlled 
to maintain pluripotency, as either higher or lower expression levels lead to a loss of 
pluripotency in ESCs (Kopp et al. 2008). Indeed, SOX2 cooperates closely with other dose-
dependent transcription factors, such as OCT4 and Nanog. Like SOX2, increasing or 
decreasing levels of OCT4 will induce differentiation in ESCs (Niwa et al. 2005). Together, 
SOX2, OCT4 and Nanog form an interdependent, core regulatory network that maintains 
self-renewal and pluripotency.  
This network is furthermore suggested to function as lineage specifiers. SOX2 promotes 
neuroectoderm differentiation, while OCT4 and Nanog regulate the differentiation of ESCs 
into mesendoderm, a common precursor of mesoderm and endoderm (Loh & Lim 2011, 
Thomson et al. 2011, Wang et al. 2012). SOX2 induces neural lineage specification through 
the repression of alternative fates by suppressing key regulators of the mesoderm, like 
Brachyury (Thomson et al. 2011, Wang et al. 2012). Upon neural specification, ESCs start to 
differentiate into neural precursor cells (NPCs), which are often referred to as neural stem 
cells. In contrast to ESCs, these neural stem cells are fate restricted and can only develop 
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into cells of the neural lineage, i.e. neurons and glia, and are thus multipotent. These neural 
progenitors maintain SOX2 expression and, as in ESCs, SOX2 functions to maintain self-
renewal and proliferation (Avilion et al. 2003). 
 
3.2   SOX IN NEUROGENESIS 
In the developing embryo, SOXB1 (SOX1, SOX2, SOX3) expression is largely restricted to 
the neuroectoderm (Wood & Episkopou 1999), which will give rise to the skin and nervous 
tissue. The nervous tissue includes neural crest and the neural tube, the latter of which will 
develop into the brain and spinal cord (= central nervous system, CNS). As most of my work 
is done in the embryonic mouse/chicken spinal cord, I will focus on SOX expression in this 
tissue in the following sections.  
Neural stem cells (=neural precursor cells, NPCs) are located in the ventricular zone of the 
developing spinal cord. NPCs express high levels of SOX1-3 (Fig 1), which are not only 
expressed simultaneously and redundantly, but also have overlapping functions in the 
maintenance of undifferentiated neural progenitor cells (Bylund et al. 2003, Graham et al. 
2003, Wood & Episkopou 1999). The functional redundancy of the SOXB1 factors has been 
demonstrated in various studies (Nishiguchi et al. 1998, Malas et al. 2003, Ferri et al. 2004). 
In general, the overexpression of any SOXB1 factor promotes proliferation and hinders 
neural differentiation, whereas inhibiting SOXB1 function causes cell cycle exit and 
premature differentiation (Bylund et al. 2003, Graham et al. 2003, Favaro et al. 2009). The 
mechanisms through which they maintain the undifferentiated state in neural progenitor 
cells is largely unknown. One mechanism is blocking the activity of proneural bHLH (basic 
helix-loop-helix) proteins like NGN2 and ASCL1 (Bylund et al. 2003).  
Thus, in order for a NPC to differentiate, SOXB1 proteins need to be downregulated. Co-
expressed with the SOXB1 proteins is a member of their SOXB2 sister group, SOX21. 
SOX21 has the opposite function of the SOXB1 members; it promotes cell cycle exit and 
neuronal differentiation (Sandberg et al. 2005, Uchikawa et al. 1999). Therefore, it is 
thought that the balance between SOXB1 and SOX21 is one of the determinants of 
whether a progenitor cell is maintained as a proliferating precursor or commits to neuronal 
differentiation. When the NPC receives extrinsic and intrinsic differentiation signals, it will 
exit the cell cycle, leave the ventricular zone, migrate laterally through the adjacent 
intermediate zone and eventually settle in the marginal zone of the developing spinal cord, 
where it initiates its physiological function as a neuron (Fig 1). This neuronal maturation is a 
stepwise process and each step is tightly regulated by a network of transcription factors. 
Proliferation and NPC genes are gradually downregulated, while neuronal markers are 
being upregulated. As the SOXB1 factors are downregulated, members of the SOXC 
(SOX4, SOX11, SOX12) group starting to be expressed. SOXC proteins can also be 
detected in NPCs, but are mostly expressed in post-mitotic differentiating neurons 
(Bergsland et al. 2006, Hoser et al. 2008). As SOXB1, SOXC factors are also expressed 
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redundantly and have overlapping functions. Overexpression of SOX4 and SOX11 in the 
developing chick spinal cord initiates a premature neuronal differentiation program as 
shown by the upregulation of pan-neuronal markers TUJ1 and MAP2. Surprisingly, these 
cells do not down-regulate SOXB1 proteins and thus, do not exit the cell cycle and remain 
proliferating (Bergsland et al. 2006). Thus, SOXC proteins play an important role in the 
acquisition of pan-neuronal characteristics. 
 
      
Figure 1. Illustration of the embryonic spinal cord (modified from Diez del Corral & Storey, 2001) and 
cross-section of a chick E4 spinal cord showing NPCs expressing SOX3 (red) and post-mitotic 
neurons expressing TUJ1 (green). 
 
3.3   SOX IN GLIOGENESIS 
Neural stem cells undergo a competence switch around day E10.5 of mouse 
embryogenesis (E5 in chick), which is referred to as the neuro- to gliogenic switch. While 
they give rise to neurons during the early stages of development, they deploy their full 
multipotent potential after the neuro- to gliogenic switch as they start to generate glial 
cells, such as astrocytes and oligodendrocytes. The SOXE member SOX9 starts to be 
expressed just slightly before the onset of gliogenesis (E9.5 in mice) and plays a key role in 
glial specification. The conditional deletion of SOX9 in the embryonic mouse spinal cord 
leads to an increase in the number of motor- and interneurons at the expense of glial cells, 
which demonstrates the importance of SOX9 for the neuro- to gliogenic switch (Stolt et al. 
2003). After specification, the glial precursor cells will generate first astrocytes and later 
oligodendrocytes. In astrocyte precursors, SOX9 induces the expression of Nuclear Factor I-
A (NFIA) and together they activate numerous important astrocytic genes, e.g. Apcdd1, 
Mmd2 and Nfe2l1 (Martini et al, 2013, Kang et al. 2012, Molofsky et al. 2013). SOX9 is the 
only SOXE member present in astrocytes and its expression is maintained throughout all 
stages of astrocyte maturation.  
The other glial subgroup, oligodendrocytes, originates from the pMN domain of the 
ventricular zone of the ventral spinal cord. NPCs in this region express the bHLH 
transcription factor OLIG2 and produce first motor neurons, before they generate 
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oligodendrocyte precursor cells (OPCs). As in astrocyte precursors, SOX9 induces the 
expression of NFIA and continues to be expressed in OPCs past the initial specification 
event (Stolt et al. 2003). However, expression levels are much lower and SOX9 executes the 
opposite function. In the OPCs of the pMN domain, SOX9 cooperates with OLIG2 to 
induce the expression of SOX10, which in turn activates many crucial oligodendrocyte 
genes (Küspert et al. 2011). With increasing levels of SOX10, SOX9 expression is decreasing 
(Stolt et al. 2003). After the induction of SOX10, NFIA now preferentially interacts with 
SOX10. Consequentially, SOX10 sequesters NFIA and thereby prevents the activation of 
astrocytic genes (Glasgow et al. 2014). Hence, even though SOX9 is required for both 
astrocyte and oligodendrocyte specification, it exerts different functions thereafter 
depending on the cellular environment and transcriptional co-factors. While it promotes 
astrocytic differentiation in astrocyte precursors, it promotes oligodendrocytic 
differentiation and the suppression of astrocytic genes in OPCs.  
Unlike in astrocytes, SOX9 is down-regulated in OPCs before the terminal differentiation. In 
contrast, SOX10 expression continues past the OPC stage and is maintained in fully 
differentiated oligodendrocytes. Terminal differentiation and myelination start at the time of 
birth and are characterized by the induction of myelin gene expression, increased lipid 
biosynthesis and myelin sheath formation. SOX10 is essential for the induction and 
maintenance of these processes, as it directly targets many key regulatory genes that are 
involved in myelination, such as Mbp and Myrf (Stolt et al. 2002, Hornig et al. 2013, Lopez-
Anido et al. 2015). Consequentially, the conditional deletion of SOX10 in mice leads to 
severe dysmyelination (Stolt et al. 2002). It activates its target genes often in cooperation 
with partner factors, like e.g. OLIG1, MYRF and TCF7L2/TCF4 (Li et al. 2007, Hornig et al. 
2013, Zhao et al. 2016). 
In summary, gliogenesis relies on SOXE factors. They are involved in and regulate each step 
from specification until terminal differentiation. Even though they are expressed (and 
operate) partly redundantly, they exert individual functions in differentiating astrocytes and 
oligodendrocytes. 
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4   GENE REGULATION IN THE CONTEXT OF 
CHROMATIN 
 
4.1   THE CHROMATIN LANDSCAPE 
Our genetic information is stored in ca. 3 billion base pairs that form, together with sugar 
and phosphate molecules, two long strands in the shape of a spiral called a double helix, 
the DNA. If stretched out, the DNA of a single cell would be about 2 m long. Hence, in 
order to fit into the microscopic cell nucleus, it does not appear as free linear strands, but is 
highly condensed and wrapped around proteins, called histones. They compact and 
organize DNA. This DNA-protein complex is called chromatin and its 3D structure has an 
enormous impact on transcriptional regulation.  
Chromatin exists in different states that are defined according to their compaction, 
accessibility and transcriptional activity (Fig 2). Heterochromatin, also called type R 
chromatin, is highly condensed and correlates with silenced transcription. These actively 
repressed domains are inaccessible and are accompanied by repressive covalent histone 
modifications, such as H3K9 or H3K27 methylation, although usually type R domains do not 
carry both marks at the same time (Ho et al. 2014). Its folded structure and the tightly 
packed histones pose a barrier to transcription factors and polymerases, leaving 
heterochromatin inaccessible to the transcriptional machinery.  
In order to initiate gene expression, the chromatin has to be opened up to allow access to 
the DNA template. This is achieved either by transiently displacing histones by chromatin 
remodeling complexes (Smith & Peterson, 2005) or by enzymatically modifying the histones 
by the addition of acetyl, methyl or phosphate groups (Fischle et al. 2005). The open, active 
chromatin is also known as chromatin type A. These active domains can usually be accessed 
by any transcription factor and are accompanied by active histone marks, such as histone 
H3 methylation on lysine 4 (H3K4me) and H3K9 and H3K27 acetylation (The ENCODE 
Project Consortium 2011). Large-scale chromatin-mapping studies have revealed that about 
half of the genome consists of vast stretches that possess neither active nor repressive 
histone marks (Ho et al. 2014, Roadmap Epigenomics Consortium et al. 2015). These 
domains are called low signal chromatin or chromatin type L. Although it is inaccessible to 
most transcription factors, pioneer factors can target this type of chromatin (Soufi et al. 
2012, van Oevelen et al. 2015) and attract chromatin modifying enzymes, resulting in either 
open, active chromatin or further compaction and the formation of repressive 
heterochromatin (see next chapter). Genome-wide mapping studies showed that active 
promoters are usually depleted of nucleosomes (Schones et al. 2008, Valouev et al. 2011, 
Teif et al. 2012). However, promoters tend to open ubiquitously among various cell types, 
as demonstrated by DNA accessibility studies (Thurman et al. 2012), suggesting that 
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ubiquitously expressed factors keep promoters accessible (Iwafuchi-Doi & Zaret 2014). In 
contrast, enhancers open in a tissue specific manner (Thurman et al. 2012). 
In summary, chromatin undergoes continuous structural changes and chromatin 
accessibility is highly dynamic. This variable access to regulatory elements provides the key 
for context and tissue specific gene expression profiles. 
 
 
Figure 2. Accessibility of different types of chromatin (Iwafuchi-Doi & Zaret, 2016) 
 
4.2   PIONEER FACTORS IN CELL FATE DECISIONS 
Pioneer factors have the unique ability to overcome the constraints of nucleosomal DNA, 
i.e. DNA wrapped around histones, and can access silent genes that have not been marked 
for activity. Subsequently, this enables the binding of other transcription factors, cofactors, 
chromatin modifying and remodeling enzymes, resulting in the assembly of a complex of 
regulatory proteins that either initiate gene expression or lead to the formation of 
heterochromatin and gene repression. The hierarchical mechanisms by which transcription 
factors engage target sites provide insights into ways to modulate the process and hence 
cell fate control (Iwafuchi-Doi & Zaret 2014). This makes pioneer factors a fundamental tool 
for understanding and altering lineage specification. Chromatin states and gene expression 
profiles are cell type specific, and genes specific to the function of one cell type may be 
antagonistic the function of another cell type (Iwafuchi-Doi & Zaret 2016). Therefore, in 
order to establish new cell fates during embryonic development, genes specific to the 
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original cell fate must be suppressed and genes specific to the new cell fate, which are 
silent and inactive, must be accessed and activated. This concept is also the basis for 
cellular reprogramming, the conversion of one specific cell type into another, which I will 
elaborate on more extensively in the next chapter. Thus, cell fate changes, naturally or 
forcibly induced, usually depend on the pioneering function of certain transcription factors. 
The mechanism of how the different pioneer factors recognize their target sites varies. The 
paradigm pioneer factor, FOXA1, binds to the full motif on one side of the DNA, leaving 
the other side free to bind core histones (Clark et al. 1993, Cirillo et al., 1998). Its binding 
displaces linker histones and keeps local nucleosomes accessible (Cirillo et al. 1998, 
Iwafuchi-Doi et al. 2016). Also SOX2 has been suggested to function as a pioneer factor, 
along with OCT4, KLF4 (Soufi et al. 2012) and the bHLH protein ASCL1 (Wapinski et a. 
2013). In contrast to FOXA1, these factors recognize only a partial DNA sequence of their 
canonical binding motifs, which is compatible with nucleosome binding (Soufi et al. 2015). 
The authors of this study analyzed the binding sites of OCT4, SOX2 and KLF4 on 
nucleosome free versus nucleosome bound loci. While all three factors bound their 
canonical motifs in nucleosome free DNA, they targeted degenerate or partial motifs in 
nucleosome wrapped regions. The binding site of SOX2 was degenerated from CTTTGT to 
CTTTNT.  
In summary, pioneer transcription factors are crucial for cell fate control and the regulation 
of transcriptional profiles in a cell type and context specific manner. Their primary 
engagement with closed chromatin enables non-pioneer factors to subsequently bind to 
these regions and initiate the secondary events that lead to appropriate gene expression. 
 
4.3   INDUCED CELL FATE CHANGES (REPROGRAMMING) 
Cellular reprogramming is the conversion of a mature and fully differentiated cell type (e.g. 
fibroblast) into another cell type. In most cases the desired cell types to be generated are 
proliferative progenitor cells, such as a NPCs or even pluripotent stem cells. However, a 
mature somatic cell can also be directly converted into a different mature somatic cell type 
without undergoing an intermediate pluripotent or progenitor state, which is referred to as 
transdifferentiation. As mentioned before, cellular reprogramming requires massive 
chromatin restructuring as the genes specific to the original cell fate must be repressed and 
genes specific to the desired cell fate must be activated. 
Cellular reprogramming is typically achieved through forced overexpression of lineage-
specific transcription factors. The most famous example of reprogramming is the conversion 
of fibroblasts into induced pluripotent stem cells (iPSCs) using only four transcription 
factors: SOX2, OCT4, KLF4 and c-MYC. This discovery by Yamanaka et al. in 2006 had an 
enormous impact on the field of regenerative medicine and was rewarded with a Nobel 
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prize in 2012. Since then, several SOX factors have been shown to be required or even 
sufficient for reprogramming, especially members of the SOXB1 and SOXE group. 
SOX2 is widely expressed in the early neuroectoderm and in neural stem and progenitor 
cells. Adequately, it has been used extensively in various combinations to induce neural 
stem or progenitor cells, but also to revert cells back to a pluripotent state. Even though it 
is mostly used in combination with other transcription factors, SOX2 alone was shown to be 
sufficient to induce NPCs from either fibroblasts (Ring et al. 2012) or astrocytes (Niu et al. 
2013). However, the generation of iPSCs with SOX2 alone has not yet been shown, 
suggesting that cofactor partnerships may be less essential for iNPC than for iPSC 
generation (Julian et al. 2017). In another interesting study from 2012, Lujan et al. narrowed 
down a pool of initially 11 neural transcription factors to a triple combination of SOX2, 
BRN2 and FOXG1 to convert mouse fibroblasts into NPCs. While the NPCs that were 
induced with this triple combination were tripotent and could be differentiated into 
functional neurons, astrocytes and oligodendrocytes, NPCs that were induced with only 
SOX2 and FOXG1 were only bipotent and lacked the potential to differentiate into 
oligodendrocytes. Moreover, whereas the transcription factors FOXG1 and BRN2 alone (but 
not SOX2 alone) were also capable of generating neural precursor cells, the addition of 
SOX2 was required for the generation of functionally mature neurons. In summary, SOX2’s 
role in reprogramming is crucial as it is required for the de-differentiation process of 
somatic cells, but also functions as a specifier for the neural lineage. 
Similarly to SOX2, the members of the SOXE group have also been attributed with the 
ability to convert fibroblasts. In combination with glial fate specifiers NFIA and NFIB, 
Caiazzo et al. (2014) showed that SOX9 can convert mouse fibroblasts into astrocytes that 
are transcriptionally and functionally comparable to native brain astrocytes. Furthermore, 
SOX9 in conjunction with KLF4 and c-MYC established induced chondrocytes from mouse 
fibroblasts (Hiramatsu et al. 2011, Tam et al. 2014). Another SOXE member, SOX10, can 
convert fibroblasts to functional oligodendrocytes when co-expressed with OLIG2 and 
NKX6.2 or ZFP536 (Najm et al. 2013, Yang et al. 2013). Like SOX2, SOX10 alone has also 
been demonstrated to be sufficient to autonomously generate multipotent neural 
progenitor cells (neural crest) from mouse and human fibroblasts (Kim et al. 2014). 
In summary, these findings indicate that several SOX factors have the capacity to induce 
restructuring of chromatin landscapes and initiate a cascade of subsequent events which 
lead to the establishment of gene expression programs that are aberrant to the original 
cell fate. 
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5   AIMS 
 
The main focus of my work lies on the transcriptional regulation of the different stages as a 
neural stem cell transitions to a neuronal or glial fate. In particular, we address the following 
questions: 
What are the mechanisms that maintain stem cell identity? What triggers cells to commit to 
a certain fate? What instructs the cell to stop proliferating, downregulate progenitor genes 
and initiate a cell type specific gene expression program? How is this cell type specific 
identity maintained? How can certain transcription factors manipulate this mature state and 
reverse it back to a proliferative state? And overall, how are these processes regulated on a 
transcriptional level and what genomic features accompany them?  
This thesis aims to illuminate the role of different SOX factors in the regulation of these 
processes and to contribute to our understanding of the mechanisms that drive neuro- and 
gliogenesis. 
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6   RESULTS AND DISCUSSION 
 
6.1   PAPER I 
Different members of the SOX transcription factor family play key sequential roles in each 
stage of neurogenesis; the differentiation process of an embryonic stem cell (ESC) to a 
neural precursor cell (NPC) to a mature neuron. But how these SOX factors regulate the 
specific gene expression programs of each stage is not well characterized. 
We have used ChIP-sequencing to generate and compare genome-wide binding data for 
SOX2, SOX3 and SOX11 in ESC derived NPCs and immature neurons, respectively. A 
comparison of the binding pattern of SOX3 in NPCs to the binding pattern of the 
transcriptional coactivator p300, which occupies active enhancers in the developing embryo 
(Visel et al. 2009), revealed that 40% of the SOX3 peaks corresponded to regions that were 
labeled as active enhancers in the brain, but not in ESCs or limb tissue. Similar results were 
observed for SOX11 peaks. Thus, many of the SOX3 and SOX11 bound regions correspond 
to functional enhancers that are active in the developing CNS. Indeed, the genes 
associated with SOX3 peaks were enriched for genes involved in CNS development. 
Interestingly, SOX3 bound not only genes that are expressed in NPCs, but also genes that 
are selectively expressed in later stages of neurogenesis, i.e. in SOX3-negative 
differentiated neurons. Surprisingly, the binding pattern of SOX3 in NPCs overlapped 
substantially with the binding pattern of SOX11 in immature neurons. This promiscuous 
binding pattern of the different SOX factors raised the question of how their unique and 
common target genes are expressed. While genes that were first bound by SOX3 and later 
by SOX11 were most significantly enriched for genes expressed in NPCs, genes targeted 
uniquely by SOX3 and SOX11 were most significantly expressed in late populations of 
neurons and glia. Thus, SOX3 binds genes that are active in NPCs as well as genes that are 
silent in NPCs and will later be bound and activated by SOX11 in differentiating neurons. 
This raised the question of how SOX factors regulate their target genes in a cell type 
restricted fashion despite their broad range of binding. Functional studies with SOX3 and 
SOX11 on isolated neuronal enhancers showed that, even though these regions were 
bound by SOX3 in NPCs, only SOX11 could activate theses enhancers and drive the 
expression of a reporter construct. The presence of SOX3 suppressed the SOX11-mediated 
activation. Additional in vitro experiments indicated that this suppression was due to 
competitive binding rather than active repression. These results suggest that SOX3 
prebinds silent neuronal genes in NPCs to prevent their premature SOX11-mediated 
induction. 
Previous studies have shown similar characteristics for SOX2, as SOX2 in ESCs binds many 
silent genes that will be activated at later stages of development (Boyer et al. 2005, Lee et 
al. 2006). Several of these genes carried active as well as repressive histone modifications. 
When we examined the SOX3 and SOX11 bound targets for these histone marks by ChIP-
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qPCR, we discovered that SOX3 bound regions expressed in NPCs carried only the active 
mark H3K4me3, whereas SOX3 bound neuronal/glial genes carried both the active 
H3K4me3 and the repressive H3K27me3 mark. As these neuronal genes become bound 
and activated by SOX11 in immature neurons, the repressive mark is lost and only the 
active modification remains. In contrast, NPC genes that were bound by SOX11 lost the 
active mark and were only associated with H3K27me3. This data was complemented with 
additional histone modification ChIP-data from a myoblast cell line misexpressing SOX3, 
and together they indicate that these SOX factors can modulate and alter histone 
modifications and induce local epigenetic changes. 
To investigate if a similar prebinding pattern can also be observed at even earlier stages of 
neurogenesis, we compared our NPC SOX3-ChIP to a SOX2-ChIP in ESCs (Chen et al. 
2008). Nearly 50% of the regions that were bound by SOX3 in NPCs were also bound by 
SOX2 in ESCs. While genes that were bound exclusively by SOX2 were mainly expressed in 
ESCs, genes sequentially bound by SOX2 and SOX3 were most highly expressed in NPCs 
and genes targeted exclusively by SOX3 were associated with neuronal and glial 
expression. Thus, similar to the prebinding of SOX3 to silent neuronal and glial genes, 
SOX2 prebinds many silent genes in ESCs that will later be targeted and activated by SOX3 
in NPCs. Furthermore, genes that were targeted by SOX2 in ESCs and carried bivalent 
histone marks were strongly expressed in NPCs, but not in progenitor populations of meso- 
or endodermal origin. Thus, in parallel to its function in maintaining pluripotent stem cells, 
SOX2 prebinding specifies neural lineage-specific gene programs. 
SOX transcription factors have been shown to function as architectural proteins that induce 
bending of DNA and local unwinding (Ferrari et al. 1992). Therefore, the prebinding of SOX 
proteins to poised genes may protect these genes from epigenetic repression, such as 
heterochromatin formation, and promote the formation of permissive chromatin, thus 
priming them for later activation. Another scenario could be that SOX binding to poised 
enhancers primes them for either later activation or terminal repression as the bivalent 
histone marks are resolved into monovalent marks at later developmental stages. 
Furthermore, SOX2 bound regions in human ESCs have been shown to be depleted of 
DNA methylation (Lister et al. 2009). Thus, in addition to preventing their premature 
expression, SOXB1 occupancy could also facilitate the later activation of genes at the 
proper developmental stage and cellular context. This mechanism has also been 
demonstrated outside of the neuronal lineage: the liver-specific enhancer of the Alb1 gene 
is prebound by FOXD3 already in ESCs, which protects this region from methylation (Xu et 
al. 2007). FOXD3 is later replaced by FOXA1 which activates this enhancer in liver cells (Xu 
et al. 2009). A prerequisite for such a cell type specific activation of SOX bound enhancers 
would be the cooperation with specific partner factors, since SOX factors alone bind DNA 
with low affinity and low specificity and, as demonstrated above, the binding of SOX factors 
does not lead automatically to an activation of the corresponding gene. 
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In summary, in addition to maintaining proliferating cells in an undifferentiated state, 
SOXB1 proteins also function to prepare these cells for differentiation by occupying and 
epigenetically predisposing genes to be activated at later steps of neurogenesis. The 
sequential binding of different SOX factors regulates coordinated lineage selection and 
maintenance from early pluripotency to later post-mitotic differentiation stages. 
 
 
Figure 3. Model depicting the sequential binding of SOX proteins to common target genes during 
the differentiation of ESCs towards the neuronal lineage, illustrating the association between SOX 
prebinding and histone modifications (Bergsland et al. 2011). 
 
6.2   PAPER II 
In this paper we follow up on our sequential binding model from paper I and expand it to 
gliogenesis. In paper I we demonstrate that SOX3 binds to silent genes in NPCs that will be 
expressed at later stages of neuro- and gliogenesis, i.e. in mature neurons and glial cells. 
We showed that SOX11 will replace SOX3 on those neuronal genes and induce their 
activation. The question that arose consequentially was, if a similar model could be 
directing the activation of glial genes. SOX9 is expressed in glial precursor cells (GPCs) and 
is essential for both astrocyte and oligodendrocyte development (Stolt et al. 2003). While it 
continues to be expressed in mature astrocytes, it is downregulated during the 
differentiation of oligodendrocytes as another SOX factor, SOX10, is starting to be 
expressed. SOX10 is required for the terminal differentiation of oligodendrocytes and the 
induction of genes involved in myelin production (Stolt et al. 2002, Hornig et al. 2013, 
Lopez-Anido et al. 2015). Thus, we speculated that SOX9 and SOX10 could replace SOX3 
on astrocyte and oligodendrocyte genes, respectively, and activate those. The first step to 
such an analysis was to define astrocyte and oligodendrocyte specific genes. Therefore, we 
performed single cell RNA-sequencing (scRNA-seq) on the developing mouse spinal cord 
and defined the transcriptomes specific to the major cell types, NPCs and GPCs as well as 
neurons, astrocytes and oligodendrocytes. Then we generated cell cultures from 
differentiating ESCs, that recapitulate the sequential generation of neurons and glial cells. 
We performed ChIP-sequencing of SOX3, SOX9, H3K27ac in GPCs (11 days of 
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differentiation) and compared the target genes to our defined cell type specific 
transcriptomes. Furthermore we ChIPped H3K27ac in NPCs (4 days of differentiation) and 
re-analyzed our SOX3 NPC-ChIP (Bergsland et al. 2011).  
The genes that were bound by SOX3 in NPCs consisted of genes that are expressed in 
NPCs/GPCs, neurons, astrocytes and oligodendrocytes. When we mapped these SOX3 
NPC-targets onto H3K27ac ChIP reads from NPCs and GPCs, we detected two clusters 
within these targets: while cluster II carried the active chromatin mark in both NPCs and 
GPCs, cluster I lost the active mark along the transition from NPCs to GPCs. Cluster I 
corresponded to genes that are expressed in NPCs, neurons and oligodendrocytes, but not 
astrocytes. In contrast, genes associated with cluster II were strongly enriched for astrocyte 
genes. Hence, even though SOX3 prebinds neuronal and glial genes in NPCs, mainly the 
astrocytic genes seem to remain active in GPCs. Even though the binding pattern of SOX3 
changes from NPCs to GPCs, 30% of the GPC targets had been prebound in NPCs. 
Astrocytic genes were most strongly enriched within these prebound genes, which is in line 
with the maintained active chromatin mark as NPCs transition to GPCs.  
SOX9, which is co-expressed with SOX3 in GPCs, targeted mainly regions that were 
associated with astrocyte and oligodendrocyte genes. Furthermore, SOX9 co-targeted 20% 
of the SOX3 bound regions and these shared targets are enriched for astrocytic genes. 
Thus, while SOX9 prebound both astro- and oligodendrocytic genes in GPCs, a specific 
feature of astrocytic genes is that they were co-bound by SOX3. To further examine the 
prebinding of SOX9 to oligodendrocytic genes and a possible subsequent binding of 
SOX10, we compared our SOX9 GPC-ChIP to a publically available SOX10 ChIP in 
oligodendrocytes (Gomez-Lopez et al. 2011). SOX9 prebound many regions in GPCs that 
would later be bound by SOX10 in mature oligodendrocytes. Those genes were mostly 
enriched for oligodendrocyte and astrocyte specific genes, which could indicate a 
repressive function of SOX10 since astrocytic genes are not expressed in SOX10 positive 
oligodendrocytes. Interestingly, no overlap could be detected between SOX10 peaks and 
SOX3 GPC-peaks. In summary, SOX9 and SOX3 co-prebind astrocyte genes in GPCs, but 
genes that are only prebound by SOX9 alone correspond to both astro- and 
oligodendrocyte genes and will subsequently be bound by SOX10 in oligodendrocytes. De 
novo motif analysis revealed the enrichment of NFI motifs among SOX9 and SOX3 co-
bound astrocytic regions. SOX9 and SOX10 bound astrocytic regions were enriched for 
EHF motifs, whereas SOX9 and SOX10 bound oligodendrocytic regions showed an 
enrichment for ZBTB3 motifs. Among these putative partner factors, only NFIA was 
significantly expressed in our scRNA-seq cell clusters. 
To investigate if SOX3 blocks glial gene expression in a similar fashion as neuronal genes, 
we cloned enhancers that were either bound by SOX3/SOX9 or SOX9/SOX10 and tested 
the regulatory function of SOX3, SOX9 and SOX10 on these. The astrocytic SOX3/SOX9 
bound elements could be activated by SOX9 and also in synergy by SOX9 and NFIA, but 
not by SOX3. Instead, SOX3 suppressed their activation by SOX9 and NFIA. While 
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astrocytic SOX9/SOX10 elements did not show an activation by any SOX factor, 
oligodendrocytic SOX9/SOX10 elements were activated by SOX9 and SOX10 in an 
additive manner. Additional experiments in vitro and in the chick spinal cord confirmed that 
SOX3 can prevent the premature onset of astrocytic gene expression. 
In this paper, we demonstrate at a genome-wide level how SOX3 and SOX9 preselect gene 
programs in NPCs and GPCs that are first activated during gliogenesis. The function of this 
prebinding could be, as discussed for paper I, to facilitate later activation, poise them for 
either later activation/terminal repression and/or to prevent their premature expression. The 
fact that SOX9 is an essential specifier of both the astrocytic and oligodendrocytic fate and 
the observation that it prebinds genes of both glial sublineages, raises the question of how 
these different target genes are regulated. We could identify a selective enrichment of the 
NFI motif only in sequences that were associated with astrocyte genes. This is in line with 
NFIA’s cooperation with SOX9 during astrocyte differentiation (Martini et al, 2013, Kang et 
al. 2012, Molofsky et al. 2013). 
 
6.3   PAPER III 
SOX2 is expressed in a variety of stem cells and has key functions in regulating fundamental 
processes of stem cells, including their maintenance, proliferation and cell fate decision. 
However, whether the common characteristics of different stem cells are regulated through 
similar transcriptional mechanisms is not well understood. To examine if and how SOX2 
regulates common and cell type specific gene sets in different stem cell populations, we 
performed SOX2 ChIP-seq on E11.5 mouse stomach and lung/esophagus tissue and 
compared it to SOX2 ChIP-seq data from E11.5 mouse cortex and spinal cord (Hagey et al. 
2016). 
We found that SOX2 binding was primarily cell-type specific and only 32 peaks were 
common between all four tissues. The SOX2 binding profile was more similar between 
tissues of the same germ layer than between endodermal and neuroectodermal tissues. 
This cell type specificity could possibly be due to interaction with distinct, tissue specific 
partner factors. De novo motif analyses revealed an enriched OTX1 motif in regions that 
were bound by SOX2 specifically in the cortex and a PAX2 motif in the regions bound in 
the spinal cord. DNA-regions targeted specifically by SOX2 in the stomach were enriched 
for GATA4 and HNF1A motifs, while those targeted in the lung/esophagus included 
FOXA1 and TEAD4 motifs. The regions that were commonly bound by SOX2 in neural and 
endodermal cells were enriched for ZEB1 and ZBTB33 binding motifs. These transcription 
factors belong to families that have been shown to interact with SOX proteins and they are 
appropriately expressed within the different tissues, which led us to investigate a potential 
physical and functional interaction with SOX2. Co-immunoprecipitations with the neuro 
specific OTX1, the endoderm specific FOXA1 and the common ZEB1 revealed a physical 
interaction between SOX2 and these transcription factors. As DNaseI treatment abolished 
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the SOX2-OTX1 complex formation, these factors’ interaction appears to be DNA-
dependent. To examine a functional interaction between SOX2 and the putative partner 
factors, we cloned enhancers that were commonly or specifically bound by SOX2 in neural 
and endodermal tissues and tested the activation potential of SOX2 in combination with 
OTX1, FOXA1 and ZEB1. CNS specific regions could be activated by SOX2 and OTX1 in an 
additive manner, while stomach specific regions were activated by SOX2 and FOXA1. 
Regions that were commonly bound by SOX2 in neural and endodermal tissues were 
activated by SOX2, but co-expression of ZEB1 repressed this activation. 
To investigate how the distinct binding patterns of SOX2 are correlated with the gene 
expression profiles of neural and endodermal tissues, we performed an RNA-seq of SOX2-
GFP+ cells isolated from the cortex, spinal cord, stomach and lung/esophagus of Sox2-Gfp 
mice. The comparison of the SOX2 bound targets with genes differentially expressed in 
cortex, spinal cord, stomach and lung/esophagus showed that cell type specific SOX2 
binding was significantly enriched around genes specifically expressed in the corresponding 
tissue. The gene ontology for those genes was enriched for cell type specific terms such as 
“pallium development”, “cell differentiation in spinal cord”, “embryo digestive tract 
development” and “lung alveolus development”. Interestingly, genes commonly bound by 
SOX2 in neural and endodermal tissue were enriched for more general GO terms such as 
“regulation of stem cell proliferation” and “regulation of stem cell differentiation”. The 
observation that the binding pattern of SOX2 reflects the gene expression profiles of the 
corresponding tissue indicated that SOX2 binding could be instructive and SOX2-bound 
regions could drive cell type specific gene expression. To examine this possibility we tested 
reporter constructs containing tissue specific or commonly bound DNA regions in zebrafish 
embryos. Even though these regions were randomly integrated into the genome, neural 
specific enhancers were predominantly activated in the CNS and endoderm specific 
enhancers predominantly in the endoderm. Common regions were activated in both 
tissues. Thus, SOX2 bound regions can function as CMRs (cis-modulatory region) and drive 
cell type specific gene expression.  
As the commonly bound genes were enriched for stem cell proliferation terms and SOX2 
has previously been shown to regulate proliferation in the developing mouse cortex in a 
dose-dependent fashion (Hagey et al. 2014), we next sought to investigate if SOX2 
regulates stem cells outside the cortex in a similar fashion. The correlation of SOX2 
expression levels and cell proliferation in the E11.5 mouse spinal cord showed that cells 
with low levels of SOX2 incorporated more BrdU than cells with high SOX2 levels, 
indicating a higher proliferation and turnover rate. As a common feature of stem cells is a 
slowly proliferative state, high levels of SOX2 promote “stemness” and maintenance of 
stem cells. In the posterior stomach, decreasing SOX2 levels between E11.5 and E15.5 
correlated with an increase of BrdU+ cells. Additional in vivo experiments in the chick spinal 
cord and mouse stomach confirmed that SOX2 dictates the rate of proliferation via cell 
cycle regulation, a mechanism similar to that in the cortex. 
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In summary, SOX2 displays functions that are common to all stem cells as well as cell type 
specific gene regulation. By maintaining stem cell identity and “stemness” via the 
repression of CyclinD1, SOX2 controls global functions in stem cells. On the other hand, 
SOX2 targets chromatin in a cell type specific fashion and its bound CRMs are instructive 
for cell type specific gene expression, likely due to cooperation with partner factors. 
 
6.4   PAPER IV 
The differentiation of a stem cell into a mature cell type is a stepwise process that is 
regulated by lineage-specific transcription factors which orchestrate changes in chromatin 
and gene expression profiles, specific for the generated cell type. However, by reactivating 
molecular programs typical of stem and progenitor cells, various studies have 
demonstrated that the differentiated state is more dynamic than previously thought. 
Reprogramming studies have shown the conversion of mature cells, e.g. fibroblast, to 
proliferating neural progenitor cells through forced overexpression of various transcription 
factors, but how these transcription factors function to impose neural fates is unclear.  
In this paper we misexpressed SOX2 and FOXG1 either alone or in combination in mouse 
embryonic fibroblasts (MEFs) to examine their initial engagement with chromatin in the 
early stages of reprogramming. Principal component analysis (PCA) and peak overlap 
revealed that the binding pattern of both factors was significantly altered in the presence of 
the other factor. Furthermore, we observed that FOXG1’s binding pattern changed more 
drastically than SOX2’s and became more similar to the binding profile of SOX2. This 
indicates that SOX2 attracts FOXG1 and instructs it to bind in close proximity. Consistently, 
we found a degenerated SOX motif enriched among sequences that were newly bound by 
FOXG1 in the double factor condition. A co-immunoprecipitation confirmed a physical 
interaction between these two factors. As SOX2 has been shown to function as a pioneer 
factor, we speculated that SOX2 can bind DNA regions that are closed in MEF cells and 
allow FOXG1 to subsequently target those regions. We analyzed our ChIP data in respect 
to publically available ATAC-seq, H3K27ac and H3K9me3 ChIP data from WT MEF cells 
(Chronis et al. 2017) and found that SOX2 displayed the ability to bind regions that are 
inaccessible in WT MEFs and devoid of the active chromatin mark H3K27ac. In contrast, 
FOXG1 bound regions that were open and carried the active mark. Interestingly, in the 
presence of SOX2, FOXG1’s binding became more similar to that of SOX2 and it bound to 
regions that were previously closed and depleted of the active mark. Notably, neither SOX2 
nor FOXG1 were able to bind to DNA regions that were enriched for the heterochromatin 
mark H3K9me3.  
Next, we were interested in the function of the genes that were targeted by these two 
factors. Surprisingly, gene ontology (GO) analysis showed that SOX2’s target genes in MEF 
cells were highly enriched for neuronal terms, both in the absence and presence of FOXG1, 
even though this enrichment was stronger in the presence of FOXG1.	   Similarly, terms 
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associated with the developing nervous system were strongly enriched among genes that 
were targeted by FOXG1 in the presence of SOX2, but underrepresented in the absence of 
SOX2.	   Strikingly, genes co-targeted by SOX2 and FOXG1 in the double-factor condition 
were strongly enriched for terms related to cellular proliferation, which is consistent with the 
finding that FOXG1 is necessary for the proper proliferation of cortical NPCs (Manuel et al. 
2011). Hence, SOX2 and FOXG1 bind to genes in MEF cells that are involved in the 
regulation of cellular proliferation and nervous system development.  
Since the expression of FOXG1 is mainly found in NPCs of the developing telencephalon 
(Tao & Lai, 1992), we next examined if this transcription factor could be involved in the 
regulation of forebrain-specific genes. To address this question, we generated transgenic 
mice that misexpress either FOXG1-IresGFP or just GFP under the control of the PAX6 
enhancer. We collected spinal cord tissue at E10.5 and the FACS sorted cells were 
subjected to RNA-seq analysis. Notably, of the 20 most deregulated genes 18 were 
upregulated including proteins involved in chromatin modification, such as the helicase 
DDX3Y, the histone demethylases DM5D and UTY, while the two most downregulated 
genes consisted of ATOH1 and WNT1. Genes that were upregulated in the FOXG1 spinal 
cord compared to the GFP spinal cord were enriched for GO terms associated with CNS 
development such as the top three terms “axon guidance”, “CNS development” and 
“synapse assembly”. Gene set enrichment analysis (GSEA) revealed several significantly 
enriched gene sets associated with brain development, for instance “forebrain generation 
of neurons”, “cerebellar cortex formation” and “telencephalon glial cell migration”. 
Furthermore, when we compared the genes that were upregulated by FOXG1 to genes 
specifically expressed in the developing mouse cortex (compared to spinal cord, Hagey et 
al. 2016), we found that 34 of the cortex specific genes were upregulated in the FOXG1-
positive spinal cord. Consistent with these findings, FOXG1 enhanced the binding of SOX2 
to genes involved in the development of anterior neural structures in MEF cells. Thus, apart 
from synergizing with SOX2 in the targeting of neural genes during early reprogramming 
events in MEFs, FOXG1 appears to also confer anterior characteristics to the targeted gene 
sets. 
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7   CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis aims to contribute to our understanding of the regulatory programs that 
orchestrate the differentiation of a stem cell into a nerve or glial cell. We have investigated 
the role of different SOX proteins in neural stem cells and subsequent cellular stages during 
neuro- and gliogenesis. We present a model of sequentially binding SOX factors that target 
genes that are active as well as genes that will become activated or repressed at later 
stages along the differentiation cascade, upon subsequent binding of another SOX factor. 
Thus, SOX proteins function to both activate specific gene sets while keeping others in a 
primed state. These primed genes are associated with bivalent chromatin marks which will 
be resolved into monovalent marks upon activation or repression. This indicates that SOX 
proteins can modulate and alter histone modifications and induce local epigenetic changes. 
Furthermore, we provide further evidence for SOX2’s role as a pioneer factor. We show that 
SOX2 can bind to regions in fibroblast cells that were silent and inaccessible and alter the 
DNA occupancy pattern of a second transcription factor, which are key indicators of a 
pioneering function. These findings only cover the initial events in the engagement of SOX 
proteins with DNA. Further studies are needed to investigate the secondary events that 
lead to subsequent changes in local chromatin structure and the assembly of large protein 
complexes at gene regulatory sequences. Another question that needs to be explored 
further is how SOX proteins confer cell type specificity to their binding and their regulatory 
function. We show that SOX factors bind relatively promiscuous and to a broad range of 
gene sets, yet they exert distinct functions depending on the cellular context and 
developmental stage. This can most likely be attributed to the association with specific 
partner factors. We have identified a few putative candidates in our studies, but more 
extensive work is needed to expand this circle and help us to gain more insight into how 
SOX factors function in the specification of neural sublineages and the mechanisms through 
which they regulate neural stem cells and their progeny. 
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